A case of pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA) syndrome successfully treated with combination therapy of corticosteroids, cyclosporine, and colchicine

Hideo Hashizume, Reiko Kageyama, Takatsune Umayahara, Tomohiro Morio

Article ID: 719
Vol 2, Issue 1, 2018, Article identifier:

VIEWS - 397 (Abstract) 180 (PDF)


Pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA) syndrome is an autoinflammatory disease characterized by destructive inflammation of the skin and joints in association with genetic mutation of the Pombe Cdc15 homology family member PSTPIP1. Because a therapeutic strategy specific to this disease has not been established, treatment is always challenging for clinicians. We herein describe a case of PAPA syndrome with typical clinical features successfully treated with combination therapy of traditional anti-inflammatory drugs. A 39-year-old man presented with painful plaques on his extremities that had been present for several years. Large brown plaques were observed on both arms and legs with numerous fistulae and ulcers. Cystic acne lesions subsequently appeared on his cheeks and upper back. We diagnosed the patient with PAPA syndrome based on the presence of typical clinical features; however, no genetic mutations of exon-1 to 15 of PSTPIP1were found. Although recent reports have emphasized the efficacy of biologics that target inflammatory cytokines such as antibodies to interleukin-1β and tumor necrosis factor-α, use of these agents remains uncovered by health insurance in Japan, showing unresolved discrepancy in practical use for clinicians. The present patient was successfully treated with combined therapy of a corticosteroid, colchicine, and cyclosporine A, encouraging the use of this combination therapy as a novel therapeutic option.


pyogenic arthritis; pyoderma gangrenosum; acne syndrome; treatment; corticosteroids; cyclosporine A; colchicine

Full Text:



Lindor NM, Arsenault TM, Solomon H, et al. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc 1997; 72(7): 611–615. doi: 10.1016/S0025-6196(11)63565-9.

Wise CA, Gillum JD, Seidman CE, et al. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 2002; 11(8): 961–969. doi: 10.1093/hmg/11.8.961.

Shoham NG, Centola M, Mansfield E, et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci USA 2003; 100(23): 13501–13506. doi: 10.1073/pnas.2135380100.

Smith EJ, Allantaz F, Bennett L, et al. Clinical, molecular, and genetic characteristics of PAPA syndrome: A review. Curr Genomics 2010; 11(7): 519–527. doi: 10.2174/138920210793175921.

Caso F, Rigante D, Vitale A, et al. Monogenic autoinflammatory syndromes: State of the art on genetic, clinical, and therapeutic issues. Int J Rheumatol 2013; 2013(19): 513782. doi: 10.1155/2013/513782.

Kondo N, Tanifuji O, Mochizuki T, et al. SAPHO syndrome in which certolizumab pegol was effective: A case report. Trends in Immunotherapy 2017;1: 93–98. doi: 10.24294/ti.v1.i2.51.

DOI: http://dx.doi.org/10.24294/ti.v2.i2.719


  • There are currently no refbacks.

Copyright (c) 2018 Hideo Hashizume, Reiko Kageyama, Takatsune Umayahara, Tomohiro Morio

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License

This site is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.